● Recruiting

A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors

Condition: Solid Tumor · Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd.

PhasePhase 1

Planned participants30

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

To Evaluate the safety and tolerability of single and multiple intratumoral injections of recombinant oncolytic virus M1 (VRT106) in patients with locally advanced/metastatic solid tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Hongyun Zhao · 020-87343565 · zhaohy@syscc.org.cn

Always discuss trial participation with your own doctor first.

Locations (3)

Sun Yat-sen University Cancer Center	Guangzhou, Guangdong, China	Recruiting
Affiliated Cancer Hospital of Zhengzhou University	Zhengzhou, Henan, China	Recruiting
Affiliated Cancer Hospital of Shandong First Medical University	Jinan, Shandong, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06368921